M. Chartier

Hospitalization at home use analysis for immune checkpoint inhibitors administrations in France: Care pathways, costs and development opportunities

Anne-Claire Toffart, Gaëtan Casanova, Morgane Pierre, H. Lemasson et autres

INTRODUCTION: The number of patients treated with immune checkpoint inhibitors (ICIs) has increased over time. Hospital-at-home (HAH) administration has been described in international studies as a model that may enhance patients' quality of life and relieve hospital capacity. The extent to which …

fr (code pays fourni par la source)

Treatment sequences of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis: A nationwide population-based study in France

Anna Molto, Laurent Arnaud, M. Chartier, Arnaud Panes et autres

fr (code pays fourni par la source)

EPH148 Insights From a French Postmarketing Authorization Early Access (MA EA) Mechanism: Projecting Clinical and Economic Benefits of Neoadjuvant Nivolumab–Platinum-Based Chemotherapy (PDC) in Resectable Non-Small Cell Lung Cancer

P. Casabianca, Stefano Lucherini, M. Chartier, Henri Leleu et autres

fr, br, gb (code pays fourni par la source)

EE168 Cost-Effectiveness of Belatacept as Conversion Therapy in the Management of Patients Living With a Renal Graft in France

M. Chartier, C Guilmet, E. Cabout, Radu Vadanici et autres

fr, us (code pays fourni par la source)

Incidence and Burden of Lower-Risk Myelodysplastic Syndrome: A Nationwide Population Study

Maud D’Aveni, M. Chartier, François-Emery Cotté, Nicolas Pagès et autres

BACKGROUND: Myelodysplastic syndromes (MDS) are hematological malignancies that primarily affect older individuals, often leading to anemia, which significantly impacts quality of life. Until now, the management of lower-risk MDS (LR-MDS) typically includes erythropoiesis-stimulating agents (ESAs) as first-line treatment, with transfusions becoming necessary …

fr (code pays fourni par la source)

Epidemiology, patient management, and survival outcomes in resected patients with non-metastatic non-small cell lung cancer: a nationwide real-world study

Stéphane Renaud, P. Casabianca, Pauline Diez-Andreu, M. Chartier et autres

INTRODUCTION: Surgery is the standard of care for eligible patients with localized or stage IIIA locally advanced non-small cell lung cancer (NSCLC) current guidelines recommend the most conservative surgeries possible. The aim of this study was to bring new real-world data on …

fr (code pays fourni par la source)

Immunosuppressive treatment patterns in kidney transplant recipients in France: an insurance claims database study (OISTER) over a 12 year period

Dany Anglicheau, Antoine Dürrbach, Isabelle Bardoulat, Mickael Arnaud et autres

BACKGROUND: The impact of new immunosuppressive strategies to prevent graft rejection on prescribing patterns is poorly documented. The objective of this study was to describe immunosuppressive medication use and survival outcomes in patients undergoing kidney transplantation in France between 2009 and 2020. …

fr (code pays fourni par la source)

Analyse médicoéconomique de nivolumab + CT néoadjuvante dans le CBNPC exprimant PDL1 ≥ 1 % en France : une stratégie moins coûteuse et plus efficace que la CT néoadjuvante

P. Casabianca, Jan E. Carette, C. Chouaid, Martina S. Harris et autres

fr, ch, gb, it (code pays fourni par la source)

95P Quality of life (QoL) and care pathway in patients with durable response to immune checkpoint inhibitors (ICI-DR) for advanced or metastatic non-small cell lung cancer (NSCLC) or melanoma: QUALICI study

N. Girard, Jean-François Bonastre, Gilliosa Spurrier‐Bernard, H. Lemasson et autres

fr, au (code pays fourni par la source)

HSD46 Care Pathway of Lung Cancer and Melanoma Patients Treated With Immune Checkpoint Inhibitors (ICI) in Hospital at Home and Administration Costs in France in 2021 and 2022

A.C. Toffart, Gabriela Casanova, M. Pierre, H. Lemasson et autres

fr (code pays fourni par la source)

PCR218 Health-Related Quality of Life (HRQoL), in Patients With Durable Response to Immune Checkpoint Inhibitors (ICIS) for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) or Melanoma: QUALICI Study

N. Girard, Charlotte Robert, Gilliosa Spurrier, H. Lemasson et autres

fr (code pays fourni par la source)

SA67 Health Care Resource Utilization and Associated Costs Among Lower-Risk Myelodysplastic Syndrome Patients in France: Edelweiss Study

Thibault Comont, J. Fernandes, M. Chartier, F.E. Cotte et autres

fr (code pays fourni par la source)